about
Human family with sequence similarity 60 member A (FAM60A) protein: a new subunit of the Sin3 deacetylase complexA novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growthThe natural tumor suppressor protein maspin and potential application in non small cell lung cancerClinical use and applications of histone deacetylase inhibitors in multiple myelomaHistone deacetylase 6 plays a role as a distinct regulator of diverse cellular processesHDAC inhibitors and immunotherapy; a double edged sword?Metabolism, longevity and epigeneticsChemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancerNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)European perspective on multiple myeloma treatment strategies in 2014Epigenetics advancing personalized nanomedicine in cancer therapyHDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulationMitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsShifts in developmental timing, and not increased levels of experience-dependent neuronal activity, promote barrel expansion in the primary somatosensory cortex of rats enucleated at birthDevelopment of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in ChinaEpigenetics in Intestinal Epithelial Cell RenewalNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative ActivityLSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivoValproate inhibits MAP kinase signalling and cell cycle progression in S. cerevisiaeHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.Screening of selective histone deacetylase inhibitors by proteochemometric modeling.Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.Invasive Cell Fate Requires G1 Cell-Cycle Arrest and Histone Deacetylase-Mediated Changes in Gene ExpressionVorinostat-like molecules as structural, stereochemical, and pharmacological toolsMelittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionAggresome formation is regulated by RanBPM through an interaction with HDAC6Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor proteinTargeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model.HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Retinoic acid and histone deacetylases regulate epigenetic changes in embryonic stem cellsA novel HDAC inhibitor with a hydroxy-pyrimidine scaffoldEffect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitorRational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A
P2860
Q24298824-E13FF089-2A3D-4EC0-A997-8A3DB1E1046EQ24309277-4CA2D695-5131-4E94-A769-ED9A34636217Q24604273-79846DAA-4351-4C61-97AF-457F989FFF2EQ26745930-16903CF5-8371-4E7A-8417-3C2D9B1FD740Q26830233-638FB13C-9836-4B44-BEF0-652232A21757Q26853102-90C119A1-6A1E-447D-BD06-681AE9B11232Q26992212-D2576BF4-BE4C-4835-A136-62DEDBAB8B38Q26998615-AAF0809B-9AED-459B-BDE3-2829510DFF05Q27004421-D80BADFC-7B68-402A-A575-FE56DD68A462Q27005966-DA4466D7-9C4C-406D-BA0A-775F0D387BF1Q27010637-875F45A4-AA49-404B-8A3D-BEC7447A4760Q27015801-6B8840CF-54FB-4CE0-AD1C-4138D09FA8E9Q27021965-B9092902-3D69-425F-B438-D27094B5C4CAQ27310013-BD8CE6A6-94E1-44AC-8D5D-D7EDD233C942Q27318094-12BB6651-8313-4C56-ABD2-F46B847A2424Q28070073-24DE1404-81F1-47D8-8BF3-70C3615BF2A8Q28071369-FB674980-0AB0-4D74-87EC-682C2DC8A19DQ28080823-8675F78A-9A59-4882-9F56-7AFA3B2215C0Q28551721-2DF56622-CE7A-4599-A028-5E10B9ACE628Q28593421-D98A43BA-BEE9-4514-B188-6F26699BA996Q28741274-05B4F055-30D5-404F-A22B-01B02AD8D008Q28821030-37212BB1-5786-4629-9D35-9234C2938C5CQ30251920-79DF2A3D-0B1F-49DF-A362-EDA2ADB9F026Q30393882-C5EE23FD-447A-4B18-BC8E-497CEA958B04Q30420578-F3BB3F64-A8EA-4084-A136-BD968A548701Q30489412-82EDFCF4-9F07-4FDE-81C1-C89CFF58E760Q30703677-1401B611-87B7-4E19-A4D8-E5DD100447C9Q33558081-7210530F-3D7F-4766-8D32-616DE2A9B4A6Q33559887-D37D6E6A-6022-406C-8EAE-419DE0ABE3B9Q33755131-8211E19C-41FC-42F0-8FFD-855C2BA9F5A4Q33757230-4D4DEB6D-564B-4B51-987F-8C9FEC3F38CFQ33785710-480A3FCA-E551-4A34-8BD3-F42FB75664E0Q33789848-DF5B0B33-00A7-4A24-9B53-7171EA871B3DQ33796184-739C7A84-056B-48E7-8396-C17B80057E04Q33818968-95538729-3B26-4861-A32F-B0B63EA4AB9AQ33842416-0577AE2E-9D20-4172-A82E-7DAAC9D6FAF3Q33888552-357632BF-F551-42CF-8AD3-873F175A4745Q33940304-6430A2AB-24FA-44F8-8BF3-52519B27C738Q33943388-D2FADDA9-BD22-43F8-8747-8094D48DB3FAQ34044049-CF48C421-4D4F-4F10-80BF-2C0C1D465767
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HDAC family: What are the cancer relevant targets?
@en
HDAC family: What are the cancer relevant targets?
@nl
type
label
HDAC family: What are the cancer relevant targets?
@en
HDAC family: What are the cancer relevant targets?
@nl
prefLabel
HDAC family: What are the cancer relevant targets?
@en
HDAC family: What are the cancer relevant targets?
@nl
P2093
P1433
P1476
HDAC family: What are the cancer relevant targets?
@en
P2093
Hedwig E Deubzer
Till Milde
P356
10.1016/J.CANLET.2008.08.016
P407
P577
2008-09-27T00:00:00Z